PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22911020-2 2013 This study was designed to investigate the role of the myocardial performance index (MPI) and serum concentrations of biomarkers (cTnT and NT-pro-BNP) in the early detection of subclinical anthracycline-induced functional alterations in children with ALL. Anthracyclines 189-202 natriuretic peptide B Homo sapiens 146-149 33817127-3 2018 This study aimed to investigate the associations of glycogen phosphorylase isoenzyme BB (GPBB), myoglobin (Mb), and brain natriuretic peptide (BNP) with anthracycline (ANT-induced cardiotoxicity (AIC)) amongst the Chinese population. Anthracyclines 153-166 natriuretic peptide B Homo sapiens 116-141 33817127-3 2018 This study aimed to investigate the associations of glycogen phosphorylase isoenzyme BB (GPBB), myoglobin (Mb), and brain natriuretic peptide (BNP) with anthracycline (ANT-induced cardiotoxicity (AIC)) amongst the Chinese population. Anthracyclines 153-166 natriuretic peptide B Homo sapiens 143-146 32868378-7 2020 Cumulative anthracycline dose (CAD) correlated with BNP (p=0.06), CMR ECV 4-chamber (p=0.05) and sagittal (p=0.01), and mitral valve E/A (p=0.02). Anthracyclines 11-24 natriuretic peptide B Homo sapiens 52-55 32069386-13 2020 CONCLUSIONS: BNP/NT-proBNP is associated with cardiotoxicity in paediatric cancer patients receiving anthracycline therapy, but owing to low sensitivity, BNP/NT-proBNP has to be evaluated in the context of further parameters including clinical assessment and echocardiography. Anthracyclines 101-114 natriuretic peptide B Homo sapiens 13-16 32069386-13 2020 CONCLUSIONS: BNP/NT-proBNP is associated with cardiotoxicity in paediatric cancer patients receiving anthracycline therapy, but owing to low sensitivity, BNP/NT-proBNP has to be evaluated in the context of further parameters including clinical assessment and echocardiography. Anthracyclines 101-114 natriuretic peptide B Homo sapiens 23-26 32454480-0 2020 Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy. Anthracyclines 89-102 natriuretic peptide B Homo sapiens 37-63 32454480-2 2020 OBJECTIVES: The aim of the present study was to investigate serial changes in levels of cardiac troponin I (TnI) and B-type natriuretic peptide (BNP) in patients treated with anthracycline-containing therapy. Anthracyclines 175-188 natriuretic peptide B Homo sapiens 117-143 32454480-2 2020 OBJECTIVES: The aim of the present study was to investigate serial changes in levels of cardiac troponin I (TnI) and B-type natriuretic peptide (BNP) in patients treated with anthracycline-containing therapy. Anthracyclines 175-188 natriuretic peptide B Homo sapiens 145-148 32454480-12 2020 The different characteristics of TnI and BNP should be considered when managing patients treated with anthracycline-containing therapy. Anthracyclines 102-115 natriuretic peptide B Homo sapiens 41-44 30275150-0 2018 The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. Anthracyclines 190-204 natriuretic peptide B Homo sapiens 50-76 30275150-1 2018 We have reported that cancer patients treated with anthracycline-based or nonanthracycline chemotherapy developed an early impairment of myocardial relaxation at echocardiography or persistent elevations of the cardiac hormone B-type natriuretic peptide (BNP). Anthracyclines 51-64 natriuretic peptide B Homo sapiens 227-253 30275150-1 2018 We have reported that cancer patients treated with anthracycline-based or nonanthracycline chemotherapy developed an early impairment of myocardial relaxation at echocardiography or persistent elevations of the cardiac hormone B-type natriuretic peptide (BNP). Anthracyclines 51-64 natriuretic peptide B Homo sapiens 255-258 31773007-7 2017 Higher levels of BNP were observed among patients receiving higher anthracycline doses (>250 mg), but not among patients with higher mean heart radiation doses. Anthracyclines 67-80 natriuretic peptide B Homo sapiens 17-20 31773007-9 2017 BNP levels significantly increased following treatment, with larger increases among patients who received higher doses of anthracyclines. Anthracyclines 122-136 natriuretic peptide B Homo sapiens 0-3 27123140-0 2016 Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Anthracyclines 56-69 natriuretic peptide B Homo sapiens 6-32 27123140-1 2016 Observational and experimental studies have produced inconsistent evidence about the association of serum levels of B-type natriuretic peptide (BNP) with anthracycline-induced cardiotoxicity (AIC). Anthracyclines 154-167 natriuretic peptide B Homo sapiens 116-142 27123140-1 2016 Observational and experimental studies have produced inconsistent evidence about the association of serum levels of B-type natriuretic peptide (BNP) with anthracycline-induced cardiotoxicity (AIC). Anthracyclines 154-167 natriuretic peptide B Homo sapiens 144-147 27123140-7 2016 The results indicated a significant difference in serum BNP levels between the cardiotoxic group and normal group, with respect to post-treatment and pretreatment with anthracyclines. Anthracyclines 168-182 natriuretic peptide B Homo sapiens 56-59 27123140-8 2016 Specifically, the serum levels of BNP increased remarkably after treatment with anthracyclines in the cardiotoxic group, compared with the normal group. Anthracyclines 80-94 natriuretic peptide B Homo sapiens 34-37 31612011-0 2019 BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer. Anthracyclines 40-53 natriuretic peptide B Homo sapiens 0-3 31612011-2 2019 Although brain natriuretic peptide (BNP) is not the ideal marker for detecting the presence of diseases of the heart, several studies have demonstrated the predictive utility of BNP in the diagnosis of anthracycline-induced cardiotoxicity (AIC). Anthracyclines 202-215 natriuretic peptide B Homo sapiens 178-181 31612011-7 2019 The concentration of BNP was significantly higher in the cardiotoxicity group during anthracycline chemotherapy (P=0.022) compared with the non-cardiotoxicity group and it was an independent predictor of cardiotoxicity (P=0.028). Anthracyclines 85-98 natriuretic peptide B Homo sapiens 21-24 31612011-8 2019 The optimal diagnostic threshold of BNP after the last anthracycline chemotherapy treatment was 107.9 pg/ml, the diagnostic sensitivity was 0.538, the specificity was 0.794, the Youden index was 0.332, the positive predictive value was 0.583 and the negative predictive value was 0.762. Anthracyclines 55-68 natriuretic peptide B Homo sapiens 36-39 31612011-10 2019 BNP elevation was associated with cardiotoxicity during the anthracycline chemotherapy. Anthracyclines 60-73 natriuretic peptide B Homo sapiens 0-3 31612011-11 2019 Detecting BNP after the final treatment of anthracycline chemotherapy may contribute to the early detection of cardiotoxicity. Anthracyclines 43-56 natriuretic peptide B Homo sapiens 10-13 29720563-0 2018 Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. Anthracyclines 162-175 natriuretic peptide B Homo sapiens 72-98 27079675-3 2016 This study explores whether cardiac biomarkers troponin I (TnI) and B-type natriuretic peptide (BNP) could be part of a screening strategy for early detection of the development of cardiotoxicity in patients undergoing anthracycline chemotherapy. Anthracyclines 219-232 natriuretic peptide B Homo sapiens 96-99 27079675-9 2016 CONCLUSIONS: The use of cardiac biomarkers, particularly BNP, may allow early detection of cardiotoxicity related to anthracycline chemotherapy. Anthracyclines 117-130 natriuretic peptide B Homo sapiens 57-60 19430339-6 2009 Moreover, increased BNP levels have been reported in asymptomatic children and adolescents pretreated with anthracyclines, who are at risk for ventricular dysfunction. Anthracyclines 107-121 natriuretic peptide B Homo sapiens 20-23 23018571-7 2012 NT-pro-BNP is a sensitive test and has a moderate relationship with the LV systolic and diastolic function, thus making it a useful cardiac marker for the monitoring of early anthracycline cardiotoxicity. Anthracyclines 175-188 natriuretic peptide B Homo sapiens 7-10 19945181-12 2011 CONCLUSIONS: LVEF and BNP modified early after anthracycline chemotherapy and LVEF did not recover at T3. Anthracyclines 47-60 natriuretic peptide B Homo sapiens 22-25 17391467-5 2007 On the other hand, increased dosage of anthracycline therapy was associated with significant raise in plasma BNP levels (r2=0.246) and significant decrease in serum TAOS levels (r2=0.317) without any change in serum cTnI levels. Anthracyclines 39-52 natriuretic peptide B Homo sapiens 109-112 9704703-0 1998 Elevated B-type natriuretic peptide levels after anthracycline administration. Anthracyclines 49-62 natriuretic peptide B Homo sapiens 9-35 19688118-2 2008 We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity. Anthracyclines 81-94 natriuretic peptide B Homo sapiens 45-70 19688118-2 2008 We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity. Anthracyclines 81-94 natriuretic peptide B Homo sapiens 72-75 19688118-8 2008 CONCLUSIONS: The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. Anthracyclines 111-124 natriuretic peptide B Homo sapiens 46-49 18850478-6 2008 Six studies, although small, suggest that BNP, NT-pro-BNP, and cTnT might be useful markers in the early detection of anthracycline-induced cardiotoxicity. Anthracyclines 118-131 natriuretic peptide B Homo sapiens 42-45 18850478-6 2008 Six studies, although small, suggest that BNP, NT-pro-BNP, and cTnT might be useful markers in the early detection of anthracycline-induced cardiotoxicity. Anthracyclines 118-131 natriuretic peptide B Homo sapiens 54-57 17171687-0 2007 B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Anthracyclines 66-79 natriuretic peptide B Homo sapiens 0-26 17171687-9 2007 CONCLUSIONS: Plasma BNP was significantly elevated in AC-treated patients with late cardiac dysfunction, although there was considerable overlap of levels between groups with and without cardiac dysfunction. Anthracyclines 54-56 natriuretic peptide B Homo sapiens 20-23 17391467-6 2007 CONCLUSION: Our study suggest that serum TAOS and BNP levels may be useful as an early and sensitive indicator of anthracycline induced cardiotoxicity. Anthracyclines 114-127 natriuretic peptide B Homo sapiens 50-53 15875778-8 2005 BNP concentrations were found to be positively correlated to anthracycline cumulative dose and negatively to LVEF values. Anthracyclines 61-74 natriuretic peptide B Homo sapiens 0-3 15875778-10 2005 CONCLUSION: An infra-clinical cardiotoxicity of anthracyclines as defined by BNP elevation is frequent but reversible. Anthracyclines 48-62 natriuretic peptide B Homo sapiens 77-80 11279304-0 2000 Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Anthracyclines 44-57 natriuretic peptide B Homo sapiens 0-25 11279304-12 2000 These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity. Anthracyclines 96-109 natriuretic peptide B Homo sapiens 39-42 9704703-3 1998 We examined the diagnostic role of B-type natriuretic peptide (BNP), a potent biochemical marker of left ventricular dysfunction, in patients administered anthracyclines. Anthracyclines 155-169 natriuretic peptide B Homo sapiens 35-61 9704703-3 1998 We examined the diagnostic role of B-type natriuretic peptide (BNP), a potent biochemical marker of left ventricular dysfunction, in patients administered anthracyclines. Anthracyclines 155-169 natriuretic peptide B Homo sapiens 63-66 9704703-6 1998 RESULTS: Of the examined cardiac biochemical markers, BNP levels alone showed marked elevations to abnormal levels after anthracycline administration. Anthracyclines 121-134 natriuretic peptide B Homo sapiens 54-57 9704703-10 1998 CONCLUSIONS: Our studies suggest the possible use of BNP levels to assess the cardiac state after anthracycline administration. Anthracyclines 98-111 natriuretic peptide B Homo sapiens 53-56